GSK plc’s Vir Biotechnology VIR Stock Holding History

GSK plc’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87.1M	Hold	8,550,954	–	–	14.47%	3
2026 Q1	$76.6M	Hold	8,550,954	–	–	12.79%	4
2025 Q4	$51.6M	Buy	+8,550,954	New	+$50.9M	6.45%	4

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

GSK plc's VIR Position: Q2 2026 in Review

GSK plc held its Vir Biotechnology (VIR) position steady in Q2 2026 at 8,550,954 shares worth $87.1M. The position accounts for 14.47% of the portfolio, ranked #3.

GSK plc first reported a position in VIR in Q4 2025 and has held it in 3 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

GSK plc held 8,550,954 shares of Vir Biotechnology worth $87.1M as of Q2 2026.
GSK plc left its Vir Biotechnology share count unchanged in Q2 2026.
Vir Biotechnology made up 14.47% of GSK plc's portfolio in Q2 2026, its #3 holding.
GSK plc first reported a position in Vir Biotechnology in Q4 2025 and has held it in 3 quarters since.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on GSK plc's 13F filing for Q2 2026, filed 13 Aug 2026.